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The role of indoleamine 2,3-dioxygenase in
LP-BPM5 murine retroviral disease progression
Megan A O’Connor1 and William R Green1,2*
Abstract
Background: Indoleamine 2,3-dioxygenase (IDO) is an immunomodulatory intracellular enzyme involved in
tryptophan degradation. IDO is induced during cancer and microbial infections by cytokines, ligation of co-
stimulatory molecules and/or activation of pattern recognition receptors, ultimately leading to modulation of the
immune response. LP-BM5 murine retroviral infection induces murine AIDS (MAIDS), which is characterized by
profound and broad immunosuppression of T- and B-cell responses. Our lab has previously described multiple
mechanisms regulating the development of immunodeficiency of LP-BM5-induced disease, including Programmed
Death 1 (PD-1), IL-10, and T-regulatory (Treg) cells. Immunosuppressive roles of IDO have been demonstrated in
other retroviral models, suggesting a possible role for IDO during LP-BM5-induced retroviral disease progression
and/or development of viral load.
Methods: Mice deficient in IDO (B6.IDO−/−) and wildtype C57BL/6 (B6) mice were infected with LP-BM5 murine
retrovirus. MAIDS and LP-BM5 viral load were assessed at termination.
Results: As expected, IDO was un-inducible in B6.IDO−/− during LP-BM5 infection. B6.IDO−/− mice infected with
LP-BM5 retrovirus succumbed to MAIDS as indicated by splenomegaly, serum hyper IgG2a and IgM, decreased
responsiveness to B- and T-cell mitogens, conversion of a proportion of CD4+ T cells from Thy1.2+ to Thy1.2-, and
increased percentages of CD11b+Gr-1+ cells. LP-BM5 infected B6.IDO−/− mice also demonstrated the development
of roughly equivalent disease kinetics as compared to infected B6 mice. Splenic viral loads of B6 and B6.IDO−/−
mice were also equivalent after infection as measured by LP-BM5-specific Def Gag and Eco Gag viral mRNA,
determined by qRT-PCR.
Conclusions: Collectively, these results demonstrate IDO neither plays an essential role, nor is required, in LP-BM5
-induced disease progression or LP-BM5 viral load.
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Background
Indoleamine 2,3-dioxygenase is an immunomodulatory
intracellular enzyme involved in the first, rate-limiting
step of tryptophan catabolism [1]. IDO expression is
induced by a variety of immune responses, including
upregulation of type I (α, β) and type II (γ) interferons
(IFNs), and following toll-like receptor (TLR) ligation
[2-5]. IDO can also be activated upon ligation of B7 co-
stimulatory molecules (CD80 and CD86) on dendritic
cells (DCs) by CD28 or CTLA-4 on T-cells [1,3,5-7].
Upon induction, high levels of IDO expression are pri-
marily found in a specialized subset of murine plasmacy-
toid dendritic cells (pDCs) expressing CD8α, CD19, and
B220, but can also be found in other cell types including
macrophages, epithelial cells, and some fibroblast-like
cells [7-10].
IDO expression induces tryptophan catabolism, resul-
ting in reduced tryptophan levels and increased levels
of toxic downstream metabolites (kynurenine, quinolic
acid, and picolinic acid), all of which can contribute to
T-cell suppression [8,11,12]. T-helper 1 (Th1) cell clones
are more sensitive to changes in tryptophan levels than
T-helper 2 (Th2) cell clones, resulting in increased Th1-
directed immunosuppression [7]. Furthermore, IDO
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induction is associated with altering the balance of T-
cell subsets, increasing the proportion of T-regulatory
(Treg) cells and decreasing T-helper 17 (Th17) cells
[2,13,14]. Overall, IDO induction causes immunosup-
pression by dampening Th1 and Th17 cellular res-
ponses and enhancing regulatory T-cell responses.
The immunosuppressive role of IDO in modulating
immune responses to cancer is well recognized, but the
role of IDO during viral infections is less well established
[15]. In microbial infections, IDO can act as either an
immune suppressor or as an anti-microbial agent, de-
pending on the nature of the infection. IDO-linked
immunosuppression occurs during in vitro Puumala
hantavirus infection [16] and in vivo during Plasmodium
species [17] and Leishmania major infections [18]. In
contrast, IDO induction acts in vitro and/or in vivo
against bacteria, such as Chlamydiae, Streptococci and
Staphylococci species [19-21]; parasites, for example
Toxoplasma gondii [21]; and viruses, including herpes
simplex-2 virus (HSV-2), cytomegalovirus (CMV), hepa-
titis B virus (HBV), and vaccinia virus infections [22-25].
Increased IDO expression occurs during human immuno-
deficiency virus (HIV) [26-29], simian immunodeficiency
virus (SIV) [13,30] and murine LP-BM5 immunodefi-
ciency-causing retroviral infections [31], yet a comprehen-
sive understanding of the effect of IDO on these retroviral
infections has not been provided. Increased IDO mRNA
levels in HIV patients have been correlated with increased
viral loads, and IDO expression decreases upon antiretro-
viral therapy (ART), suggesting a direct correlation be-
tween IDO and HIV virus propagation [27]. Additional
studies in HIV/AIDS systems have further suggested that
IDO may play an active immunosuppressive role [7,32,33].
LP-BM5 retroviral infection causes a profound and
broad immunodeficiency in susceptible mouse strains
such as C57BL/6 (B6); this disease is known as murine
AIDS (MAIDS). MAIDS is characterized by early poly-
clonal T- and B-cell activation, splenomegaly, lymphaden-
opathy, hypergammaglobulinemia, and a subsequent
progressive immunodeficiency of T- and B-cell responses
[34-37]. As with AIDS patients, this immunodeficiency
leads to an increased incidence of B-cell lineage lym-
phomas and susceptibility to a variety of opportunistic
pathogens [34,38]. In resistant BALB/c mice, we have
demonstrated a key protective role of Gag-specific CD8+
cytotoxic T-lymphocytes (CTLs), which are critical for
controlling LP-BM5 infection and protecting against
retroviral pathogenesis [38-42]. We have not been able to
detect such robustly protective CTLs in the susceptible B6
model, strongly suggesting that this CTL deficit is critical
to the disease induction.
In the LP-BM5 retroviral system immunosuppressive
mechanisms have been identified which modulate di-
sease progression. The kinetics and degree of MAIDS
pathogenesis are increased after LP-BM5 infection of B6
mice deficient for the Programmed Death 1 (PD-1) gene,
but disease can be decreased if instead the interruption
of PD-1 signaling is confined to the CD8 compartment
[43,44]. Elevated splenic anti-inflammatory IL-10 mRNA
levels are found in wildtype (w.t.) B6 mice following LP-
BM5 infection [45]. Mice deficient of the IL-10 gene are
more susceptible to MAIDS than w.t. B6 mice, presu-
mably because, as we have shown for PD-1, IL-10 may
well act to control pathogenic CD4+ T-cells that drive
LP-BM5-induced disease [43]. Our lab has examined the
role of CD4+ Tregs, and demonstrated that Forkhead
box P3 (FoxP3)+ CD4+ T-cells increase during the first
2 weeks of infection and plateau at about 18 days post
infection (dpi) [44]. Upon initial depletion of natural
Tregs, via adoptive transfer of FoxP3-CD4+ T cells into
B6.TCRαR−/− mice, which lack T cells, there was no
substantial change in disease severity [44]. However,
MAIDS pathogenesis can be reduced upon depletion of
FoxP3+CD4+ Treg cells, in combination with elimination
of PD-1 expression on CD8+ T-cells [44]. This reduction
in the degree of MAIDS seen was apparently due to the
observed expansion of a protective CD8+ CTL popula-
tion, which had previously been suppressed by FoxP3+
Tregs and/or PD-1 following the infection of intact, un-
manipulated B6 mice. These studies further suggest an
important role of immunosuppressive mechanisms in
either the promotion of, or protection from, LP-BM5-in-
duced pathogenesis.
We have also identified an immunosuppressive mo-
nocytic myeloid-derived suppressor cell (MDSC) po-
pulation (Ly6G-/lowLy6C+CD11b+) [46]. This MDSC
population increases during LP-BM5 infection and is
capable of suppressing both T- and B-cell responses, in
significant part via an inducible nitric oxide synthase
(iNOS)-dependent manner [46]. It is possible that
the immunosuppressive mechanism(s) of MDSCs in B6
mice could be regulated during LP-BM5 infection, due
to the known cross-talk between the iNOS pathway and
tryptophan catabolism in other systems [9,11]. Down-
stream metabolites of tryptophan catabolism can alter
iNOS expression; 3-hydroxyanthranilic acid (3HAA) is
able to inhibit the activity and expression of iNOS; while
picolinic acid is able to induce iNOS in conjunction
with IFNγ activation [47,48]. In short, it is becoming
appreciated that immunoregulatory mechanisms affect
LP-BM5-induced disease progression, suggesting that
immunosuppressive roles of IDO could also be playing an
important role in MAIDS pathogenesis.
We assessed the role of IDO inhibition on MAIDS
progression and LP-BM5 viral load. Compared to other
immunodeficiency-causing retroviral infections in primate
species, the LP-BM5 murine retroviral system afforded
the opportunity for a more comprehensive assessment of
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IDO, including the use of B6.IDO−/− mice. Our studies
suggest a non-essential role for IDO in LP-BM5-induced
disease, with little, if any, effect on retroviral load.
Results and Discussion
IDO is undetectable in B6.IDO−/− mice following LP-BM5
infection
The genotype of B6.IDO−/− mice was evaluated, to
confirm the absence of the normal w.t. IDO gene. PCR-
amplified products of genomic DNA were run on
agarose gels to identify the presence of either w.t. or
knockout IDO DNA. The wildtype IDO DNA signature
(427 bp) was observed only in B6 mice, and the cha-
racteristic knockout IDO DNA fragment (280 bp) was
found only in B6.IDO−/− mice (Figure 1A). Next, the
possible induction of IDO during LP-BM5 infection was
determined. B6 and B6.IDO−/− mice were infected in
parallel with LP-BM5, and splenic mRNA was assessed
at 8 weeks post infection (wpi) for the presence of IDO
message using qRT-PCR (Figure 1B). As expected, IDO
mRNA was undetectable in all uninfected and infected
B6.IDO−/− mice. In contrast, minimal levels of IDO
mRNA were detected in uninfected w.t. B6 mice and sig-
nificantly increased by 8 wpi (Figure 1B). Plasmacytoid
dendritic cells (pDCS) have been shown to be major
producers of IDO [8], but in our preliminary experi-
ments, no overall obvious difference was seen in the per-
centage of the pDC cell population at 8 wpi in B6 and
B6.IDO−/− mice (data not shown). The induction of
IDO in B6 mice after LP-BM5 infection is consistent
with a possible role for IDO in LP-BM5-induced patho-
genesis and/or viral load.
B6.IDO−/− mice succumb to MAIDS after LP-BM5
infection
To assess the role of IDO in modulating LP-BM5-in-
duced disease, B6 and B6.IDO−/− mice were infected, in
parallel, with LP-BM5 and evaluated at 8 wpi for standard
MAIDS disease read-outs. Severe splenomegaly occurred
in infected B6 and B6.IDO−/− mice at 8 wpi (Figure 2A),
Figure 1 IDO is Undetectable in B6.IDO−/− Mice Following LP-BM5 Infection. (A) Genomic DNA was isolated from B6 and B6.IDO−/− mice,
and the IDO genotypes were determined using PCR. Expected IDO band lengths: w.t. IDO (427 bp) and knockout IDO (280 bp). (B) Relative
expression of IDO splenic mRNA by qRT-PCR, as compared to β-actin. Lines represent the mean, n = 10, from three independent experiments.
IDO mRNA was not detected (ND) in uninfected or infected B6.IDO−/− mice. **p < 0.01, in comparison to uninfected controls, as determined
using one-way ANOVA.
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Figure 2 B6.IDO−/− Mice Succumb to MAIDS After LP-BM5 Infection. B6 and B6.IDO−/− mice were infected in parallel, with 5x104 pfu of
LP-BM5, and MAIDS parameters were assessed at 8 wpi. (A) Spleen weights. (B) Serum IgG2a and IgM as assessed by ELISA. (C) Emergence of
Thy1.2-CD4+ T-cells as assessed by flow cytometry. Percent of Thy1.2+CD4+ of the total CD4+ cell population, calculated from the flow plots of all
the experiments. (D) Increase in the CD11b+GR-1+ cell population, assessed by flow cytometry. Percent of CD11b+GR-1+ of total splenocyte
population, calculated from the flow plots of all the experiments. (E) Thymidine incorporation after stimulation with ConA and LPS, counts per
minute (cpm). Mitogen percent inhibition of the uninfected control to ConA and LPS responses is shown. All histograms represent the mean of
samples from four independent experiments, with indicated standard deviations. *p < 0.05; **p < 0.01, ***p < 0.001; **** p < 0.0001, in comparison
to uninfected controls, as determined using one-way ANOVA.
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the standard time-point for assessment of robust disease
[43,49]. As another parameter of the activational aspects
of LP-BM5-induced pathogenesis, sera were assessed for
IgG2a and IgM levels by ELISA (Figure 2B). MAIDS-
associated hypergammaglobulinemia was observed at 8
wpi in both B6 and B6.IDO−/− mice, for IgG2a and IgM.
During infection of B6 mice with LP-BM5, there is also
the emergence of splenic CD4+ T-cells that do not express
the characteristic Thy1.2 marker [34,50,51]. A signifi-
cant decrease in the percentage of Thy1.2+CD4+ cells
of the total CD4+ population was observed in w.t. B6,
as expected, but also in B6.IDO−/− mice by 8 wpi
(Figure 2C). As another indicator of LP-BM5 patho-
genesis during B6 infection, our lab has identified an
increase in a CD11b+Gr-1+ cell population, as early as
5 wpi [46]. Here, we further demonstrate B6.IDO−/−
mice also have a significant increase in the CD11b+Gr-1+
cell population at 8 wpi (Figure 2D). Because it is a mono-
cytic MDSC subpopulation (Ly6G-/lowLy6C+CD11b+)
from LP-BM5 infected B6 mice that is capable of sup-
pressing T- and B-cell responses, in part via an iNOS-
dependent manner [46], we also demonstrated here
that LP-BM5 infection-dependent increases in the
Ly6G-/lowLy6C+CD11b+ population are readily detectible
in B6.IDO−/−, as well as B6, mice (data not shown). Fur-
thermore, in preliminary experiments, Ly6G-CD11b+
MDSCs derived from infected B6.IDO−/− mice have
roughly similar suppressive capabilities against the re-
sponse to polyclonal LPS stimulation in comparison to
MDSCs derived from infected B6 mice (data not shown).
Lastly, immunosuppression was measured, as demon-
strated by the standard MAIDS read-out of T- and B-
cell responsiveness to polyclonal mitogen activation [51].
Isolated splenocytes from uninfected and infected mice
were stimulated with ConA or LPS, and proliferation
was assessed 72 hours post stimulation. At 8 wpi, B6
mice have a significantly decreased responsiveness to
ConA and LPS (Figure 2E). B6.IDO−/− mice also exhibit
significant and comparable levels of immunosuppression
in response to these T- and B-cell mitogens, as com-
pared to uninfected controls (Figure 2E).
Based on the collective assessment of all MAIDS pa-
rameters, B6.IDO−/− mice are susceptible to MAIDS
and experience immunodeficiency with similar severity
to B6 mice.
IDO is not required for MAIDS at different timepoints or
doses of LP-BM5
Although IDO thus appears to have little overall effect
on MAIDS at 8 wpi, the kinetics of disease progression
may differ for B6 and B6.IDO−/− mice. Timepoints ear-
lier than the standard 8 wpi endpoint determination
were therefore assessed. In these experiments, to better
compare overall disease levels, mice were first evaluated
for standard MAIDS parameters, including spleno-
megaly, hypergammaglobulinemia, responsiveness to
T- and B-cell mitogens, and emergence of Thy1.2-CD4+
T-cells, as described in Figure 2. Then disease index, as
previously described, was calculated, ranging from 0 (no
disease) to 5 (severe disease) [41]. At the standard dose
of 5×104 pfu of LP-BM5, disease kinetics between B6
and B6.IDO−/− mice were generally similar, with little
disease at 3 wpi and a gradual increase in disease
over the course of infection as assessed at 5 and 8
wpi (Figure 3A). No significant difference in the ex-
tent of disease was demonstrated between the infected
groups at any of the time points.
It was next determined if B6 and B6.IDO−/− mice
have different susceptibilities to disease after infection
by lower viral doses. B6 and B6.IDO−/− mice were
Figure 3 IDO is Not Required for MAIDS at Different
Timepoints or Doses of LP-BM5. LP-BM5-induced disease kinetics
were assessed in B6 and B6.IDO−/− mice. (A) B6 and B6.IDO−/−
mice were infected in parallel, with 5x104 pfu of LP-BM5 virus.
MAIDS parameters were assessed at 3, 5, and 8 wpi and disease
index was determined. (B) B6 and B6.IDO−/− mice were infected
with LP-BM5 at a dose of 5x103 or 1x104 pfu. Disease parameters
were assessed at 8 wpi and disease index was calculated. Histograms
represent the mean, (n = 3), with indicated standard deviations. The
patterns of the presented results are representative of two additional
experiments, which provided a similar pattern of results. *p < 0.05, in
comparison to 5x103 pfu, as determined using one-way ANOVA.
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infected in parallel with either 5×103 or 1×104 pfu of
LP-BM5, and disease index was assessed at 8 wpi
(Figure 3B). Infected B6 and B6.IDO−/− mice succumbed
to substantial, and roughly equivalent, MAIDS at these
two lower viral inoculums, with no observed signifi-
cant differences in the quantification of disease. Thus,
B6.IDO−/− mice are generally as susceptible to MAIDS at
multiple viral doses as compared to prototypic susceptible
B6 mice.
Infected B6.IDO−/− mice do not display an altered
LP-BM5 viral load
While no apparent differences were observed between
B6 and B6.IDO−/− mice in regards to susceptibility to
MAIDS progression, there may be differences in viral
load. For example, in a w.t. LP-BM5 infected B6 mouse,
IDO may not suppress the pathogenic CD4+ T cells that
are necessary for disease initiation and progression [51],
but rather IDO may have an effect on viral spread and
subsequent viral load. To address this question, splenic
mRNA was extracted from uninfected and infected B6
and B6.IDO−/− mice. Splenic mRNA was assessed for
LP-BM5-associated ecotropic (Eco) helper and defective
(Def ) Gag viral sequences. Compared to essentially no
detectable signal in uninfected mice, a significant in-
crease in Eco Gag and Def Gag mRNA was detected in
B6 and B6.IDO−/− mice (Figure 4). Furthermore, no sig-
nificant difference was observed between either Eco Gag
or Def Gag of the infected B6.IDO−/− mice in compari-
son to infected B6 mice. Thus, we could not detect dif-
ferences in accumulated retroviral load, suggesting that
LP-BM5 viral replication and spread were not substan-
tially altered in B6.IDO−/− mice.
In summary, we demonstrated that B6.IDO−/− mice
were susceptible to LP-BM5 induced disease and had
relatively equivalent levels of disease as compared to
infected B6 mice, at multiple timepoints and at varying
doses. We further demonstrated that viral load was es-
sentially unaltered in infected B6.IDO−/− mice in com-
parison to infected B6 mice. Our results are interesting
to compare to those of Hoshi, et al., who recently re-
ported an increase in IDO mRNA, protein levels, and
enzymatic activity in response to LP-BM5 infection [31].
Their results are consistent with our results herein, as
we demonstrated an increase in splenic IDO mRNA at 8
wpi (Figure 1A). However, it remains unclear whether
viral infection per se and/or the host immune response
is responsible for the induction of IDO. In any event, re-
gardless of the source(s) of the induced IDO, this re-
sponse does not appear, in itself, to be crucial in the
balance of host resistance factors versus retroviral patho-
genesis mechanisms that lead to the profound disease
observed in LP-BM5 infected, susceptible B6 mice.
Hoshi, et al. also infected B6.IDO−/− mice or treated
infected B6 mice with 1-methyl tryptophan (1MT), an
IDO inhibitor, and demonstrated an increased respon-
siveness to the T-cell mitogen ConA, in comparison to
infected B6 mice, suggesting decreased immunosuppres-
sion when IDO activity was not present [31]. However,
no uninfected control mice were reported for compari-
son, thus making it unclear what percentage of mitogen
responsiveness was restored in IDO deficient mice. In
contrast, our data demonstrate that B6.IDO−/− mice
Figure 4 Infected B6.IDO−/− Mice Do Not Display An Altered LP-BM5 Viral Load. B6 and B6.IDO−/− mice were infected in parallel, with
5x104 pfu, and splenic mRNA was extracted at 8 wpi. LP-BM5 Eco Gag and Def Gag mRNA were assessed by qRT-PCR, relative to β-actin [63].
Histograms represent the means, (n = 4), with indicated standard deviations. The patterns of the presented results are representative of three
additional experiments, which provided a similar pattern of results. **p < 0.01; ***p < 0.001; ****p < 0.0001, in comparison to uninfected controls,
as determined using one-way ANOVA.
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exhibited substantially decreased responsiveness to both
T-cell (ConA) and B-cell (LPS) mitogens in comparison
to stimulated uninfected controls, and there was no dif-
ference in the extent of immunodeficiency as compared
to infected w.t. mice (Figure 2E).
Due to these differential results in LP-BM5-induced
immunosuppression between our data and those of
Hoshi, et al., we employed a more comprehensive, yet
accepted, panel of MAIDS parameters, to obtain a broa-
der understanding of the role of IDO in LP-BM5-in-
duced disease. All MAIDS parameters examined herein
indicated LP-BM5-induced pathogenesis in infected
B6.IDO−/− at roughly equivalent levels to those of infected
B6 mice (Figures 2 and 3). Hoshi, et al. also reported de-
creased splenic viral copies of Def Gag at 8 wpi in either
infected B6.IDO−/− mice or infected B6 mice treated
with 1MT [31]. In our studies, we found no significant
difference in splenic mRNA for Def Gag and Eco Gag at
any of the tested timepoints (3, 5, and 8 wpi) (Figure 4
and data not shown). Although our LP-BM5 inoculum
and that used by Hoshi, et al. appear to be comparable
doses, we wanted to confirm that the effects seen were
not due to our administration of a larger viral dose. To
assess this, we compared three infectious viral doses, in-
cluding two that were lower than our standard inocu-
lum: 5x104, 1x104, and 5x103 pfu. However, at each dose
essentially no difference in splenic mRNA for Def or Eco
Gag was observed between infected B6 and B6.IDO−/−
mice (data not shown), consistent with our finding of no
differential levels of disease (Figure 3B). Alternatively,
variance in the proportion of the defective and ecotropic
genomes within the different LP-BM5 viral preparations
might explain the differences seen between the two stud-
ies. Whether this potential variable of the pathogenic
LP-BM5 Def Gag content or distribution among virions
is responsible for the different results obtained here,
versus by Hoshi, et al., or whether other factors are also
responsible, is unclear. Future studies to clarify the differ-
ences may be informative for a better understanding
of the regulation of LP-BM5-induced pathogenesis. In
conclusion, our data clearly demonstrate a non-essential
role of IDO in MAIDS or viral load development follo-
wing LP-BM5 infection of susceptible B6 mice.
It is also instructive to consider the effects of IDO, or
its absence, in other viral systems. IDO has been shown
to have differential effects during HSV-1 infection. In
vitro studies have demonstrated that IDO can exert an
anti-viral effect against HSV-1 infection, which appears
to be mediated in part by IFNγ and/or IL-1 [52,53]. It
was further demonstrated in vivo that mice infected with
HSV-1, which consequently developed signs of encephal-
itis, had increased levels of quinolic acid, a downstream
metabolite of tryptophan catabolism [54]. These stu-
dies suggest an anti-viral role for IDO during HSV-1
infection. However, treatment of mice with 1MT during
HSV-1 infection had no detectable effect on HSV-1 rep-
lication or on the survival of the infected mice [55].
Thus, IDO may act as an immunosuppressive molecule
during viral infections depending on the model of infec-
tion (in vitro versus in vivo), and, most likely, also by the
presence/absence of other immunomodulatory signals
within the micro-environment.
With respect to other immunodeficiency-causing ret-
roviruses, IDO has been implicated as a potential thera-
peutic target against HIV/AIDS, and the use of IDO
inhibitors has recently been explored within SIV models,
but with mixed results. In vitro studies have shown im-
proved proliferative responses of CD4+ and CD8+ T-cells
from immunosuppressed HIV-infected patients by addi-
tion of 1MT [27,33,56]. There is also in vitro evidence that
IDO acts differentially to suppress the T-cell response
against HIV infection: IDO can arrest CD4+ T cells in the
G1-S transition phase of the cell cycle, but can suppress
CD8+ T cells by reduced expression of the CD28 co-
stimulatory molecule [56]. In contrast, in vivo studies
using 1MT, to inhibit IDO, have led to variable results. In
a murine model of HIV-induced encephalitis, in which
human peripheral-blood lymphocytes (hu-PBLs) are given
to nonobese diabetic-severe combined immunodeficient
(NOD/SCID) mice and then are infected by injection of
HIV-1-infected monocyte-derived macrophages, treat-
ment with 1MT lead to an increase in the HIV-specific
CTL response and essentially elimination of HIV-infected
macrophages from the brain [33]. Similarly, SIV-infected
rhesus macaques that were treated with 1MT, and also on
antiretroviral treatment (ART), displayed reduced SIV
RNA levels in the spleen and plasma [57]. In this same
study, however, macaques not on ART and treated with
1MT exhibited no change in viral levels [57]. Likewise,
ART-treated macaques also given 1MT therapy demon-
strated transiently increased plasma levels of tryptophan,
but no reduction in kynurenine [57]. In a seemingly simi-
lar study, different results were obtained: SIV-infected
ART-treated macaques also given 1MT demonstrated no
effect on tryptophan catabolism or on viral load [58].
Clearly, more work still needs to be done to fully under-
stand the potential use of 1MT or other agents that target
IDO, or the pathways involving IDO, before its potential
to treat HIV/AIDS patients can be determined. Therefore,
the study of well-controlled animal models of retrovirus-
induced immunodeficiency will undoubtedly be important
to sort out these complex interactions and sometimes
conflicting initial results.
Conclusions
Our data demonstrate a non-essential role of IDO in
MAIDS or viral load following LP-BM5 infection of sus-
ceptible C57BL/6 mice.
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Methods
Mice
C57BL/6 (B6) mice were purchased from the National
Cancer Institute (NCI, Bethesda, MD) and housed in the
Center for Comparative Medicine and Research (CCMR)
at the Geisel School of Medicine at Dartmouth. Breeding
pairs of B6.IDO−/− mice were purchased from The
Jackson Laboratory (Ban Harbor, ME) and bred in-house
at the CCMR. All animal experiments were done with
the approval of the Institutional Animal Care and Use
Committee of Dartmouth College, and in conjunction
with the Dartmouth Center for Comparative Medicine
and Research, an AALAC approved animal facility. This
institution has an Animal Welfare Assurance on file
(A3259-01). The genetic backgrounds of B6.IDO−/−
mice were assessed at the DartMouse™ Speed Congenic
Core Facility at the Geisel School of Medicine at Dart-
mouth, which uses the Illumina, Inc. (San Diego, CA)
GoldenGate Genotyping Assay to interrogate 1449 SNPs
spread throughout the genome. The raw SNP data were
analyzed using DartMouse’s SNaP-Map™ and Map-Synth™
software, allowing the determination for each mouse of
the genetic background at each SNP location.
LP-BM5 virus inoculation
LP-BM5 retrovirus was prepared as previously described
[59,60]. All mice were given intraperitoneal injections
between 6 and 8 weeks of age with one of the following
doses: 5×104 pfu, 1×104 pfu, or 5×103 pfu of LP-BM5.
Genotyping PCR
Tail snips were taken and digested with 25 mM NaOH
and 0.2 mM EDTA for 1 hour at 98°C. 40 mM TrisHCl
(pH5.5) was added to samples and supernatant was iso-
lated after centrifugation. Genomic DNA was amplified
by PCR using primers for both w.t. IDO and knockout
IDO from The Jackson Laboratory website: w.t. IDO Pri-
mer 1: 5’-TGG AGC TGC CCG ACG C-3’, w.t. IDO Pri-
mer 2: 5’-TAC CTT CCG AGC CCA GAC AC-3’,
knockout IDO Primer 1: 5’-CTT GGG TGG AGA GGC
TAT TC-3’, knockout IDO Primer 2: 5’-AGG TGA GAT
GAC AGG AGA TC-3’. PCR products were run on a
1.5% agarose gel and visualized.
Splenocyte responses to mitogens
Splenocytes were isolated as previously described and
responses to Concanavalin A (ConA) and lipopoly-
saccharide (LPS) mitogens were measured [51]. Briefly,
splenocytes were plated in triplicate in a flat-bottom
96-well plate and stimulated with a final concentration
in the well of 0.75ug/ml of ConA, 10ug/ml of LPS or
supplemented media alone. After 72 hours, cells were
pulsed with 1uCi of [3H] thymidine (Dupont NEN,
Boston, MA) and harvested 6 hrs later for assessment of
thymidine incorporation.
ELISA determination of serum Ig
Serum hyper IgG2a and IgM were assessed by an
enzyme-linked immunosorbent assay (ELISA) as detai-
led previously [61,62]. Affinity-purified goat anti-mouse
IgG2a or IgM antibodies were used to coat 96-well
plates (Southern Biotechnology Associates, Birmingham,
AL) and the ELISA was developed using phosphate sub-
strate (p4744, Sigma-Aldrich).
Flow cytometry
Surface staining of splenocytes was performed as previ-
ously described [51]. Cells were stained with FITC-, PE-,
PerCP- and APC- conjugated fluorescent antibodies and
the resulting fluorescence was measured on FACSCalibur
or FACSCanto Instruments (BD Biosciences) to detect
murine CD4 (RM4-5), Thy1.2 (53–2.1), CD11b (M1/70),
and Gr-1 (RB6-8C5) (BioLegend and BD Biosciences). Ap-
propriate amounts of FITC-, PE-, PerCP- and APC- con-
jugated Ig isotypes were used as controls. Data were
analyzed using FlowJo software (Tree Star, Inc.).
RNA isolation and real-time quantitative PCR
Total RNA was isolated from the spleen, for quantitative
RT-PCR using RNeasy columns, including DNAse-I treat-
ment (Qiagen, Valencia, CA). DNAse-free RNA was reverse
transcribed using the iScript cDNA synthesis kit (Qiagen,
Valencia, CA). qRT-PCR was performed using SYBR Green
PCR Core kit (Applied Biosystems, Foster City, CA) on an
iCyler iQ instrument (Bio-Rad, Hercules, CA). Relative ex-
pression of Eco Gag, Def Gag, and IDO were evaluated in
comparison to β-actin controls as previously described
[63]. IDO primers were forward 5’-AGA CCA CCA CAT
AGA TGA AG-3’ and reverse 5’-CCA CCA ATA GAG
AGA CGA GGA-3’ as previously described [5].
Calculation of disease index
The disease index was calculated as previously described
[41]. Briefly, the percent disease was calculated for each
mouse after measurement of each of the standard panel
of MAIDS disease parameters (splenomegaly, serum
levels of IgG2a and IgM, responsiveness to ConA and
LPS, and percent of Thy1.2+CD4+ T-cells). Disease index
values were designated based on the percentages of dis-
ease for each parameter. Mice with less than 1% disease
were considered negative for disease and given a value
of 0, mice with 1-20% disease were assigned a value of
0.5, mice with 21-40% disease were given a value of 1,
mice with 41-60% disease were assigned a value of 2, mice
with 61-80% disease were given a value of 3, mice with
81-100% disease were assigned a value of 4, and mice with
disease greater than 100% were given a value of 5.
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